Bridge Neurotech and Butterfly Network Partner to Develop Non-Invasive Brain-Computer Interface

Bridge Neurotech has emerged from stealth with the goal of building a completely non-invasive brain-computer interface (BCI), announcing a research and development agreement with Butterfly Network through the Butterfly Embedded program. Under the multi-year agreement, Bridge will license Butterfly’s Ultrasound-on-Chip technology for its exploration of non-surgical BCIs, with payments to Butterfly for technology access and development milestones, as well as commitments to purchase Butterfly hardware.
Bridge was founded with a mission to make BCIs possible without brain surgery or implants. The company believes advances in neuroscience, semiconductors, and AI have created an opportunity to use ultrasound to image and decode brain activity through the skull, with the potential to restore function and expand human capabilities. As part of its emergence from stealth, Bridge also announced its first human research study and is now enrolling participants.
Will Biederman, Founder and CEO of Bridge Neurotech, stated that the company started because it believes the pieces are finally in place to make a non-invasive brain-computer interface possible, and that ultrasound is central to that opportunity. Biederman noted that Butterfly has already brought ultrasound onto a fully integrated semiconductor chip, giving Bridge a powerful and programmable foundation as it works toward real-time, non-invasive interaction with the brain.
Joseph DeVivo, President, Chief Executive Officer, and Chairman of Butterfly Network, said the BCI category holds enormous potential, from treating serious conditions to expanding human capabilities. DeVivo noted that one of the most fundamental challenges will be expanding that potential to the masses, and that innovators like Bridge are exploring surgery-free approaches to broaden access, adding that Butterfly is proud its Ultrasound-on-Chip technology can help advance that pursuit.
